StockData
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. (ERNA) stock

ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.63−0.06 (-3.55%)

Close on Nov 17, 2026Market cap $2.66MP/E –Yield –

Ernexa Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Ernexa Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.84M. For fiscal 2025 it was -$7.02M. The highest annual figure on record is $2.83M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.02M–
FY2024Dec 31, 2024-$15.84M–
FY2023Dec 31, 2023-$20.41M–
FY2022Dec 31, 2022-$20.98M–
FY2021Dec 31, 2021-$23.49M–
FY2020Dec 31, 2020-$8.10M-395.2%
FY2019Dec 31, 2019$2.74M+101.0%
FY2018Dec 31, 2018$1.37M+148.6%
FY2017Dec 31, 2017$549.00K+2287.0%
FY2016Dec 31, 2016$23.00K–
FY2015Dec 31, 2015-$4.18M–
FY2014Dec 31, 2014-$6.39M-466.7%
FY2013Dec 31, 2013$1.74M-19.2%
FY2012Dec 31, 2012$2.16M+275.6%
FY2011Dec 31, 2011$574.00K-79.7%
FY2010Dec 31, 2010$2.83M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.15M–
Q1 FY2026Mar 31, 2026-$2.26M–
Q4 FY2025Dec 31, 2025-$1.15M–
Q3 FY2025Sep 30, 2025-$1.27M–
Q2 FY2025Jun 30, 2025-$2.53M–
Q1 FY2025Mar 31, 2025-$2.07M–
Q4 FY2024Dec 31, 2024-$3.55M–
Q3 FY2024Sep 30, 2024-$6.29M–
Q2 FY2024Jun 30, 2024-$2.26M–
Q1 FY2024Mar 31, 2024-$3.75M–
Q4 FY2023Dec 31, 2023-$4.66M–
Q3 FY2023Sep 30, 2023-$5.83M–
Q2 FY2023Jun 30, 2023-$3.87M–
Q1 FY2023Mar 31, 2023-$6.05M–
Q4 FY2022Dec 31, 2022-$5.44M–
Q3 FY2022Sep 30, 2022-$6.12M–
Q2 FY2022Jun 30, 2022-$3.99M–
Q1 FY2022Mar 31, 2022-$5.43M–
Q4 FY2021Dec 31, 2021-$6.83M–
Q3 FY2021Sep 30, 2021-$6.42M–
Q2 FY2021Jun 30, 2021-$6.80M–
Q1 FY2021Mar 31, 2021-$3.43M–
Q4 FY2020Dec 31, 2020-$1.64M-266.6%
Q3 FY2020Sep 30, 2020-$2.41M-670.3%
Q2 FY2020Jun 30, 2020-$2.18M-490.6%
Q1 FY2020Mar 31, 2020-$1.87M-340.1%
Q4 FY2019Dec 31, 2019$983.00K+17.4%
Q3 FY2019Sep 30, 2019$422.00K+46.0%
Q2 FY2019Jun 30, 2019$559.00K+55.7%
Q1 FY2019Mar 31, 2019$780.00K–
Q4 FY2018Dec 31, 2018$837.00K–
Q3 FY2018Sep 30, 2018$289.00K–
Q2 FY2018Jun 30, 2018$359.00K-89.0%
Q1 FY2018Mar 31, 2018-$120.00K–
Q4 FY2017Dec 31, 2017-$507.00K-1094.1%
Q3 FY2017Sep 30, 2017-$1.75M–
Q2 FY2017Jun 30, 2017$3.27M–
Q1 FY2017Mar 31, 2017-$466.00K–
Q4 FY2016Dec 31, 2016$51.00K–
Q3 FY2016Sep 30, 2016-$41.00K–

More Ernexa Therapeutics figures

See a number that looks wrong?